These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8072621)

  • 1. Recombinant human erythropoietin increases interleukin-1 beta production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy.
    Takemasa A; Yorioka N; Ito T; Yamashita K; Oda H; Yamakido M
    Nephron; 1994; 67(2):245-7. PubMed ID: 8072621
    [No Abstract]   [Full Text] [Related]  

  • 2. Investigation of the influenza-like symptoms associated with recombinant human erythropoietin therapy.
    Takemasa A; Yorioka N; Yamakido M
    J Int Med Res; 1997; 25(3):127-34. PubMed ID: 9178144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of interleukin-1 beta production may be involved in unresponsiveness to erythropoietin therapy.
    Takemasa A; Yorioka N; Yamakido M
    Int J Artif Organs; 1996 Nov; 19(11):633-7. PubMed ID: 8970830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations.
    Steffensen G; Aunsholt NA; Povlsen JV
    Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased ultrafiltration after erythropoietin-induced correction of renal anemia in patients on continuous ambulatory peritoneal dialysis.
    Steinhauer HB; Lubrich-Birkner I; Dreyling KW; Hörl WH; Schollmeyer P
    Nephron; 1989; 53(1):91-2. PubMed ID: 2779711
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoietin escape in five CAPD patients.
    Williams P; Jones J
    Nephron; 1996; 73(2):354. PubMed ID: 8773387
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of human recombinant erythropoietin on dialysis efficiency in CAPD.
    Steinhauer HB; Lubrich-Birkner I; Schollmeyer P
    Contrib Nephrol; 1991; 89():214-23. PubMed ID: 1909946
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of anaemia in CAPD patients with recombinant human erythropoietin.
    Ramello A; Malcangi U; Bruno M; Perosa P; Reina E; Rizzuto A; Nasini MG; Carozzi S
    Adv Perit Dial; 1990; 6():308-11. PubMed ID: 1982834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin and peritoneal dialysis.
    Digenis GE; Yatzidis H
    Int J Artif Organs; 1990 Jun; 13(6):344-6. PubMed ID: 2199378
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of cytokines in the response to erythropoietin in hemodialysis patients.
    Goicoechea M; Martin J; de Sequera P; Quiroga JA; Ortiz A; Carreño V; Caramelo C
    Kidney Int; 1998 Oct; 54(4):1337-43. PubMed ID: 9767553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of tumour necrosis factor-alpha production by recombinant human erythropoietin may contribute to failure of therapy.
    Takemasa A; Yorioka N; Ueda C; Amimoto D; Taniguchi Y; Yamakido M
    Scand J Urol Nephrol; 2000 Apr; 34(2):131-5. PubMed ID: 10903076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of recombinant human erythropoietin on anemia and dialysis: efficiency in patients undergoing CAPD.
    Schollmeyer P; Lubrich-Birkner I; Steinhauer HB
    Contrib Nephrol; 1990; 87():95-104. PubMed ID: 2093545
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of renal anemia with recombinant human erythropoietin.
    Schaefer RM; Hörl WH; Massry SG
    Am J Nephrol; 1989; 9(5):353-62. PubMed ID: 2679093
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of long-term treatment with human recombinant erythropoietin in patients on CAPD.
    Steinhauer HB
    Adv Exp Med Biol; 1989; 260():157-65. PubMed ID: 2624242
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of human recombinant erythropoietin on plasminogen activator inhibitor, and protein C and S activity.
    Steffensen G; Aunsholt NA
    Am J Nephrol; 1996; 16(5):453-4. PubMed ID: 8886186
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease.
    Schreiber S; Howaldt S; Schnoor M; Nikolaus S; Bauditz J; Gasché C; Lochs H; Raedler A
    N Engl J Med; 1996 Mar; 334(10):619-23. PubMed ID: 8592524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recombinant human erythropoietin on soluble interleukin 2 receptor (SIL-2R) levels in haemodialysis patients.
    Altun B; Erdem Y; Haznedaroğlu I; Gürsoy M; Yasavul U; Turgan C; Cağlar S; Kirazli S
    Nephrol Dial Transplant; 1995 Nov; 10(11):2164. PubMed ID: 8643199
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of recombinant human erythropoietin on interleukin-1 beta and interleukin-6 in patients on maintenance hemodialysis.
    Sayinalp N; Erdem Y; Haznedaroğlu IC; Dündar S; Cağlar S; Kirazli S
    Clin Nephrol; 1995 Dec; 44(6):404. PubMed ID: 8719556
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietin may improve the ultrafiltration in peritoneal dialysis: a case report.
    Gloor HJ; Tosi G
    Perit Dial Int; 1990; 10(4):306-7. PubMed ID: 2096935
    [No Abstract]   [Full Text] [Related]  

  • 20. Erythropoietin--trials then tribulation.
    Stewart WK
    Scott Med J; 1991 Feb; 36(1):3-4. PubMed ID: 1903215
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.